| [1] | Huang S., Ong S., McKenzie D., et al. (2024). Comparison of (18)F-based PSMA radiotracers with [(68)Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 27:654−664. DOI:10.1038/s41391-023-00755-2 |
| [2] | Fendler W. P., Eiber M., Beheshti M., et al. (2023). PSMA PET/CT: Joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur. J. Nucl. Med. Mol. Imaging 50:1466-1486. DOI:10.1007/s00259-022-06089-w. |
| [3] | Cornford P., van den Bergh R. C. N., Briers E., et al. (2024). EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: Screening, diagnosis, and local treatment with curative intent. Eur. Urol. 86:148−163. DOI:10.1016/j.eururo.2024.03.027 |
| [4] | Prive B. M., Israel B., Janssen M. J. R., et al. (2024). Multiparametric MRI and (18)F-PSMA-1007 PET/CT for the detection of clinically significant prostate cancer. Radiology 311:e231879. DOI:10.1148/radiol.231879 |
| [5] | Yanagisawa T., Matsukawa A., Rajwa P., et al. (2025). Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. DOI:10.1038/s41391-025-01034-y. |
| Jin C., Zhou R., Zhang X., et al. (2026). Practical guideline for prostate specific membrane antigen positron emission tomography / computed tomography in prostate cancer. The Innovation Oncology 1:100013. https://doi.org/10.59717/j.xinn-oncol.2026.100013 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Suggested practical guideline for PSMA PET/CT in prostate cancer.